TCTR20170503002已完成未知
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of Darutab (Darunavir 600 mg) Tablets of The Government Pharmaceutical Organization, Bangkok, Thailand, with Prezista (Darunavir 600
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- All
入选标准
- •a) Non-smokers, Normal, Healthy, adult, human, subjects between 18 and 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
- •b) Having a Body Mass Index (BMI) between 18.0 and 25.0 (both inclusive), calculated as weight in kg/height in m2.
- •c) Not having significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12 lead ECG, and chest X-ray recordings (P/A view).
- •d) Able to understand and comply with the study procedures, in the opinion of the investigator.
- •e) Able to give voluntary written informed consent for participation in the trial.
- •f) In case of female subjects:
- •i. Surgically sterilized at least 06 months prior to study participation;
- •ii. If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
- •iii. Serum pregnancy test must be negative.
排除标准
- •a) Known hypersensitivity or idiosyncratic reaction to Darunavir, Ritonavir or any of the excipients or any other related drug.
- •b) History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •c) Ingestion of a medicine (CYP3A4 substrates, alfuzosin, cisapride, colchicine, dronedarone, dihydroergotamine, ergotamine, lovastatin, methylergonovine, oral midazolam, pimozide, ranolazine, rifampin, sildenafil (for treatment of pulmonary arterial hypertension), simvastatin, St. John’s Wort, and triazolam including herbal remedies) at any time within 14 days prior to the first ritonavir dosing in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •d) Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
- •e) The presence of clinically significant abnormal laboratory values during screening.
- •f) Consumption of Grapefruits or its products within a period of 72 hours prior to first ritonavir's administration in period-I.
- •g) A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or Consumption of alcohol or alcoholic products within 48 hours prior to first ritonavir's administration in period-I.
- •h) Smokers or who have smoked within last 06 months prior to start of the study.
- •i) Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •j) History or presence of seizure or psychiatric disorders.
- •k) A history of difficulty with donating blood.
- •l) Difficulty in swallowing oral solid dosage form like tablet or capsule.
- •m) Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product within 90 days prior to receiving the first ritonavir's administration in period-I. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.
- •Note: If subject had participated in a study or donated blood in which blood loss was ≤ 200 mL, subject may be dosed 60 days after the last sample of previous study or after the blood donation.
- •n) A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
- •o) A positive test result for HIV (I and/or II) antibody.
- •p) An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the first study drug in Period-I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •q) Nursing mothers (females).
研究者
相似试验
尚未招募
不适用
An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of HEPASOF (400 mg) (Sofosbuvir 400 mg Tablets) of The Government Pharmaceutical Organization, Bangkok, Thailand with Sovaldi (Sofosbuvir 400 mg Tablets) of Patheon Inc., Canada in Normal, Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female volunteersTCTR20180530002The Government Pharmaceutical Organization46
尚未招募
1 期
An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of GPO-Hep C (Sofosbuvir/Velpatasvir 400/100 mg/tablets) of The Government Pharmaceutical Organization, Bangkok, Thailand with EPCLUSA (Sofosbuvir/Velpatasvir 400/100 mg/tablets) of PATHEON INC., Canada in Normal, Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female volunteersTCTR20200224005The Government Pharmaceutical Organization54
尚未招募
1 期
An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Fully Replicate Bioequivalence Study of TENO-AF (25 mg) (Tenofovir alafenamide 25 mg Tablets) of the Government Pharmaceutical Organization, Thailand with Vemlidy (Tenofovir alafenamide 25 mg Tablets) of PATHEON INC., Canada in Normal, Healthy, Adult Human Subjects under Fed ConditionsHealthy male and female volunteersTCTR20200914002The Government Pharmaceutical Organization44
尚未招募
不适用
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of Atazanavir GPO (Atazanavir 300 mg) Capsules of The Government Pharmaceutical Organization, Thailand with REYATAZ (Atazanavir 300 mg) Capsules of AstraZeneca Pharmaceuticals LP, USA, in Normal, Healthy, Adults Human Subjects under Fed ConditionsHealthy volunteersTCTR20180217003The Government Pharmaceutical Organization52
尚未招募
1 期
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of HEPA-EN (Entecavir 0.5 mg Tablets) of The Government Pharmaceutical Organization, Thailand with Baraclude (Entecavir 0.5 mg Tablets) of AstraZeneca Pharmaceuticals LP, USA for BristolMyers Squibb Company, USA in Normal, Healthy, Adults Human Subjects under Fasting ConditionsHealthy male and female subjects.TCTR20201109006The Government Pharmaceutical Organization28